Sino Biopharmaceutical Limited
| Company type | Public |
|---|---|
| Industry | Pharmaceutical |
| Founded | 2000 |
| Headquarters | China |
Area served | China |
| Products | Biopharmaceutical and chemical medications for cancer, hepatic diseases, respiratory diseases, and perioperative pain management |
Sino Biopharmaceutical Limited (|Hang Seng Index constituent) (), commonly known as Sino Biopharm, ranks among the foremost pharmaceutical conglomerates in China. Since its initial public offering on the Hong Kong Stock Exchange in 2000, the company has been included in several prominent indices: it entered the MSCI China Index in 2013, was incorporated into the Hang Seng Index in 2018, and subsequently featured in the Hang Seng China Enterprises Index (2019), Hang Seng Connect Biotech 50 Index, as well as the Hang Seng China (Hong Kong-listed) 25 Index in 2020.
The corporation’s principal subsidiaries encompass Chia Tai Tianqing Pharmaceutical Group Co. Ltd. (“CT Tianqing”), Beijing Tide Pharmaceutical Co. Ltd., Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd., Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd., Jiangsu Chia Tai Qingjiang Pharmaceutical Co., Ltd., alongside invoX Pharma Limited. Sino Biopharm’s extensive product range includes biopharmaceutical and chemical medications designed to address cancer, hepatic conditions, respiratory disorders, and perioperative pain management.